Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PVLA Palvella Therapeutics

盘后交易 09-16 17:51:54 EDT

151.43

+0.21

+0.14%

盘后151.43

+0.000.00%

16:46 EDT

最高155.18	最低150.76	成交量19.98万
今开152.54	昨收151.22	日振幅2.93%
总市值21.82亿	流通市值12.72亿	总股本1,441万
成交额3,045万	换手率2.38%	流通股本839.81万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":151.43,"timestamp":1789588800000,"preClose":151.22,"halted":0,"volume":199783,"hourTrading":{"tag":"盘后","latestPrice":151.43,"preClose":151.43,"latestTime":"16:46 EDT","volume":5225,"amount":791221.75,"timestamp":1789591567386,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0013887051977252212,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"盘后交易","change":0.21,"latestTime":"09-16 17:51:54 EDT","open":152.54,"high":155.18,"low":150.755,"amount":30454129.37932,"amplitude":0.029262,"askPrice":198.15,"askSize":2,"bidPrice":131.87,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":151.22,"preHourTrading":{"tag":"盘前","latestPrice":151.41,"preClose":151.22,"latestTime":"07:16 EDT","volume":47,"amount":7084.52056,"timestamp":1789557378813,"change":0.19,"changeRate":0.001256,"amplitude":0.039611},"postHourTrading":{"tag":"盘后","latestPrice":151.43,"preClose":151.43,"latestTime":"16:46 EDT","volume":5225,"amount":791221.75,"timestamp":1789591567386,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.981714,"impliedVol":0.4909,"impliedVolPercentile":0.0398},"requestUrl":"/m/hq/s/PVLA","defaultTab":"news","newsList":[{"id":"1102714475","title":"Palvella Therapeutics任命全国知名儿科皮肤科专家James R. Treat博士为首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=1102714475","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102714475?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:32","pubTimestamp":1788953534,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，任命在美国颇具声望的儿科皮肤科专家James R. Treat博士出任首席医疗官一职。作为全国公认的儿科皮肤科权威，他在罕见皮肤病诊疗领域拥有卓越建树，有望为Palvella的在研管线注入新的学术动力与临床洞察。Palvella Therapeutics是一家专注于罕见皮肤病创新疗法开发的临床阶段生物制药公司，此次引入重量级医学人才，再次彰显了公司构建高水平临床团队、加速核心产品管线的坚定决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197527612","title":"Palvella Therapeutics完成向FDA滚动提交Qtorin™雷帕霉素新药申请，用于治疗微囊性淋巴管畸形","url":"https://stock-news.laohu8.com/highlight/detail?id=1197527612","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197527612?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:31","pubTimestamp":1788175870,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，已圆满完成向美国食品药品监督管理局（FDA）滚动提交Qtorin™雷帕霉素的新药申请（NDA）。该药物旨在针对微囊性淋巴管畸形这一罕见病症提供治疗方案。\n此次提交标志着该公司在推进这一潜在疗法走向临床应用的进程中，迈出了关键性的一步。Qtorin™作为一种新型雷帕霉素制剂，其开发聚焦于满足微囊性淋巴管畸形患者群体中尚未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188021390","title":"Palvella Therapeutics加速美国上市筹备，Qtorin雷帕霉素若获批有望于2027年上半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1188021390","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188021390?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:31","pubTimestamp":1788175869,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics正全力推进美国市场的上市前准备工作，为旗下产品Qtorin雷帕霉素可能于2027年上半年获批上市铺平道路——前提是最终获得监管机构的批准。该公司目前正密集开展各项筹备工作，以应对潜在的市场准入需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142355864","title":"Palvella Therapeutics任命罕见病生物技术资深高管兼商业领袖Matt Pauls加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1142355864","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142355864?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:32","pubTimestamp":1782819120,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，任命在罕见病生物技术领域成就卓著且拥有丰富商业领导经验的高管Matt Pauls加入其董事会。Pauls先生持有法学博士学位及工商管理硕士学位，他的加入将为公司带来战略与商业运营方面的专业见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158097855","title":"Palvella Therapeutics向FDA滚动提交Qtorin™雷帕霉素治疗微囊型淋巴管畸形新药申请的首个模块","url":"https://stock-news.laohu8.com/highlight/detail?id=1158097855","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158097855?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:30","pubTimestamp":1782732648,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics公司已向美国食品药品监督管理局（FDA）滚动提交了其用于治疗微囊型淋巴管畸形的在研药物Qtorin™雷帕霉素新药申请（NDA）的首个模块。此举标志着该药物正式进入监管审批的关键阶段。滚动提交允许公司在完成所有申请模块前分阶段递交材料，旨在加速整体审评流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146242398","title":"FDA批准对Palvella公司Qtorin™雷帕霉素新药申请进行滚动审评，用于治疗微囊性淋巴管畸形","url":"https://stock-news.laohu8.com/highlight/detail?id=1146242398","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146242398?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:31","pubTimestamp":1782127866,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已同意对Palvella Therapeutics公司旗下产品Qtorin™雷帕霉素的新药申请（NDA）启动滚动审评程序，该药物旨在治疗微囊性淋巴管畸形。\n这一决定意味着Palvella公司可以分阶段提交NDA的相关模块，而无需等待所有资料完全齐备，从而有望加速整体的审评流程。Qtorin™雷帕霉素是一种针对罕见病微囊性淋巴管畸形开发的局部治疗药物。\n获得滚动审评资格通常表明监管机构认为该药物针对的疾病领域存在未满足的医疗需求，并且初步提交的临床数据展现了积极的潜力。此举为Palvella公司推进该候选药物的上市进程提供了重要助力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139686968","title":"Palvella Therapeutics宣布完成Qtorin™雷帕霉素治疗微囊型淋巴管畸形的新药申请前会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1139686968","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139686968?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:30","pubTimestamp":1780486224,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，已成功完成与美国食品药品监督管理局（FDA）就Qtorin™雷帕霉素用于治疗微囊型淋巴管畸形（Microcystic Lymphatic Malformations）的新药申请前会议。此次会议是该公司推进该候选药物研发进程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103509440","title":"Palvella Therapeutics公布Qtorin™ Rapamycin治疗皮肤静脉畸形II期Toiva试验新数据，亮相第83届皮肤病研究学会年会","url":"https://stock-news.laohu8.com/highlight/detail?id=1103509440","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103509440?lang=zh_cn&edition=full","pubTime":"2026-05-15 19:33","pubTimestamp":1778844792,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics公司宣布，其用于治疗皮肤静脉畸形的Qtorin™ Rapamycin在II期Toiva临床试验中取得的最新数据，已于第83届皮肤病研究学会年会上公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129505162","title":"Palvella Therapeutics宣布首位患者接受快速通道药物Qtorin™雷帕霉素治疗临床显著性血管角化瘤的二期Lotu试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1129505162","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129505162?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:32","pubTimestamp":1777894342,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics（股票代码：PVLA）迎来重要研发里程碑——其获得快速通道认定的创新药Qtorin™雷帕霉素，已正式启动针对临床显著性血管角化瘤的二期Lotu临床试验，并完成首位患者给药。该突破性进展标志着公司在罕见皮肤病治疗领域迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101160402","title":"Palvella Therapeutics任命罕见皮肤病领域权威皮肤科医生John D. Doux博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1101160402","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101160402?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:34","pubTimestamp":1776080044,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics近日宣布，正式任命约翰·D·杜克斯医学博士、工商管理硕士加入其董事会。杜克斯博士是皮肤医学领域的资深专家，尤其在罕见皮肤疾病的研究与临床治疗方面享有盛誉。此次人事变动将为公司带来宝贵的专业见解和行业领导力，进一步强化其在罕见皮肤病治疗领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139195793","title":"异动解读 | Palvella Therapeutics新药申请进展顺利，盘中大涨9.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139195793","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139195793?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:40","pubTimestamp":1774964431,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics(PVLA)今日盘中大涨9.42%，引起了市场的广泛关注。消息面上，生物制药公司Palvella Therapeutics宣布，其针对微囊性淋巴管畸形的在研药物Qtorin Rapamycin的新药申请正稳步推进，预计将按原定计划于2026年下半年提交监管机构。该时间表标志着公司在推进该创新疗法上市进程中迈出关键一步，增强了投资者对公司研发管线进展和未来商业化前景的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162347775","title":"Palvella公司Qtorin Rapamycin治疗微囊性淋巴管畸形的新药申请按计划将于2026年下半年提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1162347775","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162347775?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:33","pubTimestamp":1774956825,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics宣布，其针对微囊性淋巴管畸形的在研药物Qtorin Rapamycin的新药申请正稳步推进，预计将按原定计划于2026年下半年提交监管机构。该时间表标志着公司在推进该创新疗法上市进程中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111986483","title":"Palvella Therapeutics将于2026年3月31日召开2025财年全年业绩电话会议并公布公司最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1111986483","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111986483?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:30","pubTimestamp":1774351813,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，计划于2026年3月31日举行2025财年全年财务业绩电话会议。此次会议将详细披露公司全年财务表现，并就业务运营、研发管线及战略规划提供最新动态。\n投资者及公众可通过指定渠道接入会议，与管理层直接交流，深入了解公司发展近况与未来展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129093196","title":"Palvella Therapeutics任命罕见病商业领袖Jennifer J. Mcdonough为市场准入与患者服务高级副总裁，强化领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1129093196","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129093196?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:35","pubTimestamp":1774265729,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布了一项重要人事任命，罕见病领域的商业领袖Jennifer J. Mcdonough已加入公司，担任市场准入与患者服务高级副总裁。这一举措旨在加强公司的领导团队实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509407655","title":"Palvella Therapeutics(PVLA.US)获TD Cowen首次覆盖，给予买入评级, 目标价44.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407655","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509407655?lang=zh_cn&edition=full","pubTime":"2025-02-05 20:11","pubTimestamp":1738757515,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics(PVLA.US)获TD Cowen首次覆盖，给予买入评级, 目标价44.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/05201147968471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TD","LENZ","PVLA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0314},{"period":"3month","weight":0.3426},{"period":"6month","weight":0.3275},{"period":"1year","weight":1.7681},{"period":"ytd","weight":0.4447}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":-0.0244},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.1479},{"period":"1year","weight":0.146},{"period":"ytd","weight":0.1107}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Palvella Therapeutics, Inc.在内华达的法律下成立于2013年5月24日。该公司是一家生物技术公司，历史上发现并开发了基于Anticalin蛋白的药物，以独特和变革性的方式靶向已验证的疾病途径。2024年3月27日，公司实施了措施，以最大限度地提高其从其合作候选药物临床管道收集潜在里程碑的能力，并保持其考虑其他战略选择的能力。该公司的临床管线包括与合作者合作的免疫肿瘤学或IO双特异性药物，包括靶向PD-L1和4-1BB的S095012（也称PRS-344）、靶向CD228和4-1BB的SGN-BB228（也称PRS-346）以及靶向GPC3和4-1BB的BOS-342（也称PRS-342）。Anticalin蛋白是公司专有的，是一类新型疗法，已在临床上通过与领先制药公司的合作关系得到验证。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.069248},{"month":2,"riseRate":0.545455,"avgChangeRate":0.088954},{"month":3,"riseRate":0.454545,"avgChangeRate":0.004194},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.071975},{"month":5,"riseRate":0.454545,"avgChangeRate":0.145935},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.054496},{"month":7,"riseRate":0.666667,"avgChangeRate":0.148037},{"month":8,"riseRate":0.666667,"avgChangeRate":0.116281},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.083674},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.050324},{"month":11,"riseRate":0.545455,"avgChangeRate":0.066832},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.051298}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Palvella Therapeutics(PVLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Palvella Therapeutics,PVLA,Palvella Therapeutics股票,Palvella Therapeutics股票老虎,Palvella Therapeutics股票老虎国际,Palvella Therapeutics行情,Palvella Therapeutics股票行情,Palvella Therapeutics股价,Palvella Therapeutics股市,Palvella Therapeutics股票价格,Palvella Therapeutics股票交易,Palvella Therapeutics股票购买,Palvella Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Palvella Therapeutics(PVLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}